BPC-157
Regulatory
Legal Status in 2026
No FDA approval for human use in the US; sold only as a research chemical.
This compound has no FDA approval for human use in the United States and is not available through licensed US pharmacies or compounding channels. It has not completed the clinical trials required for FDA approval. It may be sold online as a research chemical without quality controls, purity verification, or dosing standards. Always consult a physician.
About
About BPC-157
A synthetic 15-amino-acid peptide derived from human gastric juice proteins, BPC-157 (Body Protection Compound-157) demonstrates cytoprotective and regenerative properties in preclinical studies. Research in animal models suggests it may accelerate healing of tendons, ligaments, muscle, and gastrointestinal tissue through mechanisms involving angiogenesis, growth factor modulation, and nitric oxide pathway regulation. While extensively studied in rodent injury models, human clinical trial data remains limited, and the compound is not currently approved for therapeutic use by major regulatory agencies.
Science
Mechanism of Action
BPC-157 stabilizes growth factor receptors (including VEGF and EGF receptors), promotes angiogenesis through upregulation of nitric oxide synthase, activates the FAK-paxillin pathway to accelerate cell migration and tissue repair, and modulates the dopaminergic and serotonergic systems. Its cytoprotective effects in the gut appear to involve upregulation of prostaglandin synthesis and maintenance of mucosal integrity.
Dosing
Typical Protocol
Injection: 250–500 mcg subcutaneously or intramuscularly once or twice daily, ideally proximal to the injury site. Cycles typically run 4–12 weeks. Oral/nasal: 250–500 mcg daily; primarily used for systemic or GI effects rather than localized tissue repair. Cycle structure: Many practitioners recommend 4–8 weeks on followed by 4 weeks off.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Evidence
Evidence Tier
Evidence primarily from animal studies, cell cultures, or small pilot human trials. Results are promising but have not yet been confirmed in large-scale human RCTs. Effects in humans may differ from animal models.
Availability
Provider availability
BPC-157 has no FDA approval for human use and is not available through licensed US prescribing or compounding channels, so Vial does not list providers for it.
Compound comparisons
Compare BPC-157
BPC-157 set against other compounds people weigh it against.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.